Last
Update:
April 02, 2015
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
| |
Monotherapy with boosted PIs as an ART simplification strategy in
clinical practice.
Santos JR, Llibre JM, Berrio-Galan D,
et al
J Antimicrob Chemother. 2014 Dec
18
Abstract
Efficacy of a reduced dose of Darunavir/RTV in a cohort of
antiretroviral-naïve and experienced HIV-infected patients: a medium-term
follow-up.
Lanzafame M, Lattuada E, Rigo F, Hill A, Vento S
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):
Abstract
Bioavailability and bioequivalence of a darunavir 800-mg tablet
formulation compared with the 400-mg tablet formulation.
Kakuda TN, Leopold L, Timmers M, et al
Int J Clin Pharmacol Ther. 2014 Sep;52(9):805-16.
Abstract |
| |
|
Antiviral activity and CSF concentrations of 600/100 mg of
darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Di Yacovo MS, Moltó J, Ferrer E, et al
J Antimicrob Chemother. 2015 Jan 20.
Abstract
Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining
a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
Pinnetti C, Lorenzini P, Cozzi-Lepri A, et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19809
Abstract
Dimerization of HIV-1 protease occurs through two steps relating
to the mechanism of protease dimerization inhibition by darunavir.
Hayashi H, Takamune N, Nirasawa T, et al
Proc Natl Acad Sci U S A. 2014 Aug 4.
Abstract
Lack of mitochondrial toxicity of darunavir, raltegravir and
rilpivirine in neurons and hepatocytes: a comparison with efavirenz.
Blas-García A, Polo M, Alegre F,
et al
J
Antimicrob Chemother. 2014 Jul 9
Abstract
Evaluation of Atazanavir and Darunavir Interactions with Lipids
for Developing pH-Responsive Anti-HIV Drug Combination Nanoparticles.
Duan J, Freeling JP, Koehn J, et al
J Pharm Sci. 2014 Jun 19.
Abstract
Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding
of Darunavir to Wide Open Flaps.
Zhang Y, Chang YC, Louis JM, et
al
ACS Chem Biol. 2014 Apr 16.
Abstract
Investigation on the mechanism for the binding and drug
resistance of wild type and mutations of G86 residue in HIV-1
protease complexed
with Darunavir by molecular dynamic simulation and free energy calculation.
Li D, Zhang Y, Zhao RN, et
al
J Mol Model. 2014 Feb;20(2):2122.
Abstract
Cellular HIV reservoir replenishment is not affected by
blip or intermittent viremia episodes during darunavir/ritonavir
monotherapy.
Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Gutiérrez-Valencia A, et al
AIDS. 2013 Dec 19
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Interindividual and Intraindividual Variability’s of
Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug
Experienced HIV Patients Receiving Salvage Regimens.
Baroncelli S, Villani P, Galluzzo CM,, et al
Ther Drug Monit. 2013 Sep 20.
Abstract
Determination of P-glycoprotein surface expression and
functional ability after in vitro treatment with darunavir or raltegravir in
lymphocytes of healthy donors.
Tempestilli M, Gentilotti E, Tommasi C, et al
Int Immunopharmacol. 2013 May 23
Abstract
GAM analysis of the relationship between DRV PK and
pharmacodynamics following DRV/r 800/100 mg qd in the phase III trials ARTEMIS
and ODIN.
Kakuda T, Tomaka F, Van De Casteele T, Vangeneugden T.
J Int AIDS Soc. 2012 Nov
11;15(6):18338.
Abstract
No change of plasma darunavir concentrations by switching from
ritonavir soft capsule to tablet.
Shibata M, Takahashi M, Fukushima N,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18360.
Abstract
Darunavir plasma level in HIV overweight patients.
Poupard M, Boussairi
A, Krause J, Khuong-Josses M.
J Int AIDS Soc. 2012 Nov 11;15(6):18359.
Abstract
Darunavir is predominantly unbound to protein in cerebrospinal
fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory
concentration.
Croteau D, Rossi SS, Best BM,
et
al
J Antimicrob Chemother. 2012 Nov 9
Abstract |
Darunavir: A Critical Review of Its Properties, Use and Drug
Interactions.
Ruela Corrêa JC, D’Arcy DM, Dos Reis Serra CH, et al
Pharmacology. 2012 Jul 12;90(1-2):102
Abstract
Single and Multiple Dose Pharmacokinetics of Darunavir plus Ritonavir and
Etravirine
in Semen and Rectal Tissue of HIV-Negative Men.
Brown KC, Patterson KB, Jennings SH,
J Acquir Immune Defic Syndr.
2012 May 18.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Determinants of darunavir cerebrospinal fluid concentrations: impact of
once-daily dosing and
pharmacogenetics.
Calcagno A, Yilmaz A, Cusato J,
et al
AIDS.
2012 May 2.
Abstract |
Origin of Decrease in Potency of Darunavir and Two Related Antiviral
Inhibitors Against HIV2
Compared to HIV1 Protease.
Kar P, Knecht V
J Phys Chem B.
2012 Jan 26.
Abstract |
Effects of darunavir/ritonavir-based therapy on metabolic and
anthropometric parameters in women and
men over 48 weeks.
Currier JS, Martorell C, Osiyemi O,
et al
AIDS Patient Care STDS.
2011 Jun;25(6):333-40.
Abstract
Positive Impact of HIV-1 Gag Cleavage Site Mutations on Virological
Response to Darunavir
Boosted with Ritonavir.
Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S,
t
al
Antimicrob Agents Chemother.
2011 Jan 31
Abstract
Darunavir concentrations exceed the protein-corrected
EC50 for wild-type HIV in the semen of
HIV-1-infected men.
Taylor S, Jayasuriya AN, Berry A, Gilleran G,
et al
AIDS. 2010
Aug 25
Abstract |
800 mg Darunavir tablets prepared by hot melt
extrusion.
Thommes M, Baert L, Rosier J.
Pharm Dev Technol.
2010 Aug 23.
Abstract |
Low frequency of intermittent HIV-1 semen excretion in patients treated by
darunavir/ritonavir (
600/100 mg BID) + 2 nucleoside reverse transcriptase inhibitors or monotherapy.
Lambert-Niclot S, Peytavin G, Duvivier C, et al
Antimicrob Agents Chemother.
2010 Aug 16
Abstract |
Trends in uptake of recently approved antiretrovirals within a
national healthcare system.
Belperio P, Mole L, Boothroyd D,
Backus L.
HIV Med.
2009 Oct 23.
Abstract |
Intracellular ‘boosting’ of darunavir using known transport
inhibitors in primary PBMC.
Kwan WS, Janneh O, Hartkoorn R, et al
Br J
Clin Pharmacol. 2009 Sep;68(3):375-80
Abstract |
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
Identification of new genotypic cut-off levels to predict the efficacy
of lopinavir/ritonavir and
darunavir/ritonavir in the TITAN trial.
Hill A, Marcelin AG, Calvez V.
HIV Med. 2009
Jul 6.
Abstract
|
|
Role of tenofovir in HIV and hepatitis C virus
coinfection.
Tuma P, Vispo E, Barreiro P, Soriano V.
Enferm Infecc Microbiol Clin.
2008 Jun;26(Supl.8):31-37
Abstract
|
TMC114,
a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor
Active
against Protease Inhibitor-Resistant Viruses, Including a Broad
Range of Clinical Isolates.
De Meyer S, Azijn H, Surleraux D, et al
Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21.
Abstract
|
|
| |
Animal
Studies
